Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysis

作者：Fabio Salomone, Massimo Di Maïo, Angela Viggiano, Luigi Liguori, Carminia Maria Della Corte, Giuseppe Viscardi, Fabiana Vitiello, Fabiana Napolitano, Antonio Santaniello, A. Nuccio, Simeone D’Ambrosio, Filippo Vitale, Annarita Avanzo, Alessandra Bulotta, Luigi Formisano, Roberto Ferrara, Roberto Bianco, Valter Torri, Alberto Servetto · 发表于：Critical Reviews in Oncology/Hematology · 年份：2025 · DOI：10.1016/j.critrevonc.2025.105092 · 被引用次数：1 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Research Studies、Inflammatory Biomarkers in Disease Prognosis

BACKGROUND: The ability of progression-free survival (PFS) and overall response rate (ORR) to predict overall survival (OS) outcomes in cancer trials is matter of debate. Herein, we investigated whether PFS and ORR predicted OS results in randomized clinical trials (RCTs) testing immune checkpoint inhibitors (ICIs) in advanced NSCLC. METHODS: (≥0.7 strong, 0.69-0.50 moderate, <0.5 weak). RESULTS: =0.79). CONCLUSIONS: Across trials investigating ICIs in advanced NSCLC, PFS and ORR demonstrated various degrees of relationship with OS. Caution should be taken when efficacy of novel ICIs regimens is evaluated only using surrogate outcomes.